<DOC>
	<DOCNO>NCT00184691</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate efficacy tolerance new growth hormone ( GH ) formulation , treatment child bear retarded intrauterine growth , start age 2 5 year . Trial Design : The study multicenter , open label , parallel , randomize , Phase IIIb , control .</brief_summary>
	<brief_title>Growth Hormone Treatment Children Born With Retarded Intrauterine Growth Age 2-5 Years</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>IUGR define birth length and/or weight low limit ( &lt; P10 ) Lubchenco curve gestational age . Chronological age = 25 year HV average CA Insufficient catchup growth ( Height &lt; P3 chronological age , accord Hern√°ndez ) Parental height great equal 2 SDS average , , 160 cm father 148 cm mother Normal response GH stimulation test ( great tan equal 10 ng/mL ) Bone age ( measure Greulich Pyle method ) less equal CA Children bear multiple pregnancy Children postischemic encephalopathy Recorded malformative syndrome associate short stature ( SilverRussell , Rubinstein Taybi , Seckel etc . ) Any metabolic endocrinological disorder ( diabetes mellitus , diabetes insipidus , congenital metabolic disorder , exception thyroid disease correct replacement therapy ) Any type growth retardation associate infection , embryopathies severe chronic disease ( hemopathies , hepatopathies , malabsorptive pathology , neurologic alteration ... . ) Nutritional disorder ( celiac disease ) osteodystrophies Patients receive receive treatment ( anabolic drug , sex steroid , etc . ) likely interfere GH effect Abnormal karyotype Neoplasms Previous ongoing chemotherapy and/or irradiation Renal dysfunction , define serum creatinine &gt; 1 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>